SINTX Technologies Inc Dossier
Qualitative Analysis
Business overview
SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company that develops, manufactures, and commercializes silicon nitride technologies primarily for medical applications. The company's proprietary silicon nitride biomaterials are designed to promote bone growth, resist bacteria and viruses, and improve medical imaging compared to traditional metals and polymers. SINTX is executing a strategic pivot away from low-margin industrial OEM contracts and armor manufacturing toward proprietary biomedical devices, surgical implants, and medical-grade silicon nitride technical manufacturing.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Evolving from traditional subtractive ceramic manufacturing toward more scalable, digitally enabled production methods, including AI-assisted 3D manufacturing.
Expected impact: Improves design flexibility, shortens development cycles, and expands collaboration opportunities with contract manufacturers and strategic partners.
Developing silicon nitride material in 3D-printable filament, extruded rod, and sheet stock formats, alongside selling antipathogenic fibrous material technologies in products like sutures, mesh, and wound dressings.
Expected impact: Diversifies revenue streams by transitioning SINTX into a platform-driven biomaterials company with multiple potential licensing and partnership pathways.
Focusing exclusively on high-margin, high-growth opportunities in orthopedic and surgical markets by divesting non-core assets and terminating non-strategic operations.
Expected impact: Eliminated associated liabilities, reduced contingent liabilities, and enabled greater strategic focus and capital efficiency.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To enter the foot and ankle fusion market and accelerate SINTX's shift from R&D to revenue generation. The acquisition added six implant systems, a 510(k) pre-submission, and a commercial leadership team.
Financial impact: Added a portfolio of FDA-reviewed implants and new technologies, positioning the company for commercial scale and revenue growth starting in 2026.
Strategic Partnerships
SINTX continues to provide spinal interbody devices to CTL/Amedica, with over 50,000 devices successfully implanted to date, representing a key established commercial relationship.
Terms: Ongoing product supply revenue based on commercial orders.